Co-Diagnostics Q2 FY26 earnings call CODX

The company achieved a major milestone with the submission of its dual 510(k) and CLIA waiver to the FDA for the Flu A, B, and RSV assay on the Co-Dx PCR platform. This submission followed extensive analytical validation, including 27 individual studies and over 10,000 upper respiratory PCR test runs, and a clinical study involving more than 1,400 symptomatic patients across 9 US sites. This is a foundational step for US market entry and broader respiratory testing, with a well-established reimbursement code expected to facilitate go-to-market strategies for point-of-care locations.

Significant progress is being made in India with clinical studies for the CoSara PCR MTB test. The company is targeting submissions to India's CDSCO and WHO ERPD later this year, leveraging its CoSara joint venture for manufacturing and regulatory expertise. Participation in the UNOPS Global Implementation Workshop highlights international recognition, and recent WHO guidance on near point-of-care molecular testing aligns closely with their platform design, creating a compelling path to market in high-need regions.

Co-Diagnostics successfully completed a proof-of-concept study for an Ebola assay with direct from plasma sampling, marking its first blood-based assay and demonstrating the platform's flexibility beyond traditional swab-based testing. The CoSara team also rapidly advanced Bundibugyo virus detection, responding to a request for 200 tests from India's C-CAMP for third-party evaluation, showcasing the platform's ability to address emerging public health emergencies.

The company is investing in a connected ecosystem designed to combine molecular diagnostics, a mobile application, and secure cloud-based infrastructure, with AI-enabled capabilities under evaluation. This architecture supports decentralized testing, secure reporting, remote system management, and real-time data access, creating valuable situational awareness. The cloud-based infrastructure is planned for expansion to every regulatory region with instruments operating, including India and Saudi Arabia.

The CoMira joint venture in Saudi Arabia is advancing, with technology transfer activities underway and plans for localized manufacturing. This strategy mirrors the India approach, aiming to leverage domestic production for competitive advantages and future expansion into additional markets across the Middle East and North Africa. The company also unveiled its future automated manufacturing line to support increased production capacity as its global footprint expands.

The Vector Smart business continues to build commercial momentum, expanding its customer footprint across mosquito abatement districts nationwide. This demonstrates the versatility of the company's technology and its ability to address broader public health applications beyond traditional clinical diagnostics. By enabling in-house molecular testing, abatement districts can reduce turnaround times, validating the decentralized testing strategy for infectious disease applications.

The company reported reduced total operating expenses to $6.3 million, reflecting disciplined expense management, including lower general and administrative and research and development expenses due to headcount reductions and lower stock-based compensation. While anticipating continued operating losses in the near term, management prioritizes investments in clinical pipelines and regulatory submissions, evaluating various capital sources like equity, debt, strategic transactions, partnerships, and non-dilutive grants.